股票行情快报：天臣医疗（688013）2月9日主力资金净卖出159.56万元

Core Viewpoint - Tianchen Medical (688013) shows positive financial performance with significant year-on-year growth in revenue and net profit, indicating strong operational capabilities and market position [2]. Financial Performance - For the first three quarters of 2025, Tianchen Medical reported a main revenue of 244 million yuan, an increase of 20.66% year-on-year [2]. - The net profit attributable to shareholders reached 71.95 million yuan, up 68.29% year-on-year [2]. - The net profit after deducting non-recurring items was 66.20 million yuan, reflecting a 71.85% increase year-on-year [2]. - In Q3 2025, the company achieved a quarterly main revenue of 87.66 million yuan, a 26.4% increase year-on-year [2]. - The quarterly net profit attributable to shareholders was 23.73 million yuan, up 70.74% year-on-year [2]. - The quarterly net profit after deducting non-recurring items was 21.92 million yuan, marking a 72.61% increase year-on-year [2]. - The company's debt ratio stands at 11.3%, with investment income of 2.56 million yuan and financial expenses of -10.87 million yuan [2]. - The gross profit margin is reported at 63.22% [2]. Stock Performance - As of February 9, 2026, Tianchen Medical's stock closed at 42.98 yuan, with an increase of 1.03% [1]. - The turnover rate was 1.18%, with a trading volume of 9,606 hands and a transaction amount of 41.13 million yuan [1]. - On February 9, the net outflow of main funds was 159.56 thousand yuan, accounting for 3.88% of the total transaction amount [1]. - The net outflow of speculative funds was 357.49 thousand yuan, representing 8.69% of the total transaction amount [1]. - Retail investors saw a net inflow of 517.05 thousand yuan, which is 12.57% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, one institution has given a buy rating for Tianchen Medical [3].